IN THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application.

- 1. (Currently amended) A stable modified antibody formulation comprising:
- a) a modified antibody in an aqueous solution, the modified antibody comprising an antibody fragment and at least one nonproteinaceous polymer covalently attached to the antibody fragment; and
- b) a buffer that maintains the aqueous solution pH at about 3.5 to 6; and wherein said antibody formulation is stable at 25° C. for at least twelve weeks.
- 2. (Cancelled)
- 3. (Currently amended) The formulation of claim 1 The method of claim 1, wherein the at least one nonproteinaceous polymer is at least one poly(ethyleneglycol) polymer.
- 4. (Original) The formulation of claim 3, wherein the at least one poly(ethyleneglycol) polymer is at least two methoxypoly(ethylenegylcol) polymers.
- 5. (Currently amended) The formulation of claim [4] 34 wherein the at least two methoxypoly(ethyleneglycol) polymers are covalently attached to a lysine residue linked to the succinimide moiety.
- 6. (Cancelled)
- 7. (Original) The formulation of claim 1, wherein the modified antibody is present at a concentration of about 50 mg/ml to about 300 mg/ml.
- 8. (Currently amended) The formulation of claim 1 32, wherein less than about 5% of a succinimide ring of the succinimide moiety is present in hydrolyzed form.
- 9. (Original) The formulation of claim 1, wherein less than about 5% of the modified antibody is present in an aggregated form.
- 10. (Original) The formulation of claim 1, wherein the buffer is an acetate buffer.
- 11. (Original) The formulation of claim 1, wherein the formulation is isotonic.
- 12. (Previously presented) The formulation of claim 10, wherein the formulation further comprises a tonicifying amount of salt.
- 13.-28. (Cancelled)

- 29. (Previously presented) The formulation of claim 12, wherein the salt is sodium chloride.
- 30. (Previously presented) The formulation of claim 1, wherein the pH range is pH 4.0 to 5.5.
- 31. (Previously presented) The formulation of claim 1, wherein the pH range is pH 4.5 to 5.0.
- 32. (Previously presented) The formulation of claim 1, wherein the antibody fragment is covalently attached to nonproteinaceous polymer through a linker comprising a succinimide moiety.
- 33. (New) The formulation of claim 32, wherein the at least one nonproteinaceous polymer is at least one poly(ethyleneglycol) polymer.
- 34. (New) The formulation of claim 33, wherein the at least one poly(ethyleneglycol) polymer is at least two methoxypoly(ethylenegylcol) polymers.
- 35. (New) The formulation of claim 1, wherein the pH is about 5.5.
- 36. (New) The formulation of claim 1 wherein the said antibody formulation is stable at 40° C. for at least twelve weeks.